研究疾病:
|
心脏神经官能症(赫依盛型心悸症)
|
研究疾病代码:
|
|
Target disease:
|
Cardiac neurosis (Hessian palpitations)
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
在蒙医治疗原则指导下,采用蒙医赫依盛型心悸症症状分级量表评估安神补心六味丸改善心脏神经官能症(赫依盛型心悸症)临床症状为主要疗效结局,同时评估其改善心脏神经官能症伴随焦虑、抑郁、失眠等症状的疗效和临床安全性,明确安神补心六味丸的临床定位和治疗优势,为蒙医传统医学防治心脏神经官能症提供有力的循证医学证据和防治策略,促进安神补心六味丸在临床防治心血管病中的推广和应用。
主要目的:
通过随机双盲安慰剂对照的适应性富集设计临床研究,采用蒙医赫依盛型心悸症症状分级量表评估安神补心六味丸改善心脏神经官能症(赫依盛型心悸症)临床症状。
次要目的:
1.观察安神补心六味丸对心脏神经官能症患者心脏自主神经功能、抑郁焦虑及躯体化相关症状的影响,探索性地评价安神补心六味丸治疗心脏神经官能症患者临床症状体征的疗效;
2.观察安神补心六味丸治疗心脏神经官能症的不良反应发生情况;探索性评价安神补心六味丸治疗心脏神经官能症的安全性;
3.整理、挖掘传统蒙医医学在防治心血管病中的作用、特色和临床价值。
|
Objectives of Study:
|
Under the principle of Mongolian medicine therapy, the use of Mongolian medicine h type according to sheng palpitation disease symptoms rating scale assessment nerves bushing the six flavors pill to improve cardiac neurosis (Hector in sheng palpitation disease) clinical symptoms as the primary efficacy end, simultaneously evaluate the improvement of cardiac neurosis symptoms such as anxiety, depression, insomnia, efficacy and clinical safety, clear nerves bushing clinical location and treatment of the six flavors pill advantage, for the traditional Mongolian medicine prevention and treatment of cardiac neurosis provide strong evidence of evidence-based medicine and the prevention and control strategy, promote the nerves bushing the six flavors pill the popularization and application in clinical prevention and treatment of cardiovascular disease.
Main Purpose:
A randomized double-blind placebo-controlled adaptive enrichment design clinical study was conducted to evaluate the improvement of Anshen Buxin Liuwei Pill on the clinical symptoms of cardiac neurosis (Heyisheng palpitation) by using the Mongolian medicine Heyisheng palpitation symptom scale.
Secondary Purpose:
1. To observe the effects of Anshen Buxin Liuwei Pills on cardiac autonomic nervous function, depression, anxiety and somatization related symptoms of patients with cardiac neurosis, and to explore the efficacy of Anshen Buxin Liuwei Pills in treating clinical symptoms and signs of patients with cardiac neurosis;
2. To observe the occurrence of adverse reactions of Anshen Buxin Liuwei Pills in the treatment of cardiac neurosis; To explore the safety of Anshen Buxin Liuwei Pills in the treatment of cardiac neurosis.
3. To sort out and explore the role, characteristics and clinical value of traditional Mongolian medicine in the prevention and treatment of cardiovascular diseases.
|
药物成份或治疗方案详述:
|
成分:牛心、木香、枫香脂、丁香、肉豆蔻、广枣
|
Description for medicine or protocol of treatment in detail:
|
Ingredients: cow heart, wood, maple balsam, clove, nutmeg, jujube
|
纳入标准:
|
(1)年龄≥18岁,≤75岁;
(2)符合心脏神经官能症的诊断标准:患者有心悸、心前区疼痛、胸闷气短、呼吸困难、头晕、失眠多梦、手足发冷、多汗等心血管症状与神经系统失调症状;
(3)符合蒙医赫依盛型心悸症的诊断标准;
(4)无冠心病诊断的客观依据(符合以下任意一项);
①活动平板试验阴性;
②冠脉造影或冠脉CTA提示管腔狭窄≤50%;
③运动或药物负荷核素检查结果提示无心肌缺血。
(5)患者入组前2周内未服用抗焦虑抑郁药物或精神类药物;
(6)签署知情同意书。
|
Inclusion criteria
|
1. Aged >= 18 and <=75 years;
2. It meets the diagnostic criteria of cardiac neurosis: the patient has heart palpitations, precardiac pain, chest shortness of breath, dyspnea, dizziness, insomnia and dreaminess, hand and foot chills, sweating and other cardiovascular symptoms and neurological disorders;
3. It meets the diagnostic criteria of Mongolian medicine Heyisheng type palpitation;
4. No objective basis for the diagnosis of CHD (conforms to any of the following);
(1) The movable plate test was negative;
(2) Coronary angiography or coronary CTA indicated lumen stenosis <= 50%;
(3) No myocardial ischemia was found by exercise or drug stress radionuclide examination.
5. Patients did not take anti-anxiety and depression drugs or psychotropic drugs within 2 weeks before enrollment;
6. Signed the informed consent.
|
排除标准:
|
(1)伴有器质性心脏病,重度心肺功能不全者;
(2)高血压控制不良者(治疗后收缩压≥160mmHg或舒张压≥100mmHg);
(3)伴有恶性心律失常者;
(4)应用心脏起搏器者;
(5)合并甲状腺功能亢进症者;
(6)合并严重肝肾功能损害(ALT、AST或TBIL>2倍正常参考值上限,或Cr>1.5倍正常参考值上限);
(7)合并造血系统等严重原发性疾病、精神病者;
(8)SAS≥70分;
(9)SDS≥73分;
(10)伴随任何其它严重的疾病或状况如:恶性肿瘤;
(11)妊娠期、哺乳期妇女;
(12)过敏体质或对研究药物已知成分过敏者;
(13)近3个月内参加其它临床研究者;
(14)根据研究者的判断,受试者不适合接受研究观察。
|
Exclusion criteria:
|
(1) Patients with organic heart disease and severe cardiopulmonary insufficiency;
(2) Poor hypertension control (post-treatment systolic blood pressure >= 160mmHg or diastolic blood pressure >= 100mmHg);
(3) Patients with malignant arrhythmia;
(4) Patients with cardiac pacemakers;
(5) Patients with hyperthyroidism;
(6) Severe hepatic and renal function impairment (ALT, AST or TBIL>2 times the upper normal reference value, or CR BBB>5 times the upper normal reference value);
(7) Complicated with hematopoietic system and other serious primary diseases, mental illness;
(8) SAS >= 70 points;
(9) SDS >= 73 points;
(10) Accompanied by any other serious disease or condition such as: malignant tumor;
(11) Women in pregnancy or lactating period;
(12) People with allergies or allergies to known ingredients of the study drug;
(13) Participated in other clinical researchers within the last 3 months;
(14) In the Investigator's judgment, the subjects were unsuitable for study observation.
|
研究实施时间:
Study execute time:
|
从From
2021-04-01
至To
2023-01-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-04-01
至To
2022-06-30
|